trending Market Intelligence /marketintelligence/en/news-insights/trending/Ks05GJDIR3T7Ys0b4onoFQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Roche's Tecentriq combo gets US FDA nod for hard-to-treat lung cancer type

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Roche's Tecentriq combo gets US FDA nod for hard-to-treat lung cancer type

Roche Holding AG said the U.S. Food and Drug Administration approved Tecentriq, combined with chemotherapy, for treating adults with a hard-to-treat type of lung cancer.

The approval is for Tecentriq, in combination with chemotherapy drugs carboplatin and etoposide, as a first-line treatment for adults with extensive-stage small cell lung cancer, or ES-SCLC.

ES-SCLC is a lung cancer type that has spread too far for surgery or radiation to work as initial therapy, leaving patients with limited options for treatment.

The approval is based on results from the phase 3 IMpower133 study, which showed Tecentriq plus chemotherapy extended the lives of patients with ES-SCLC longer compared with those receiving chemotherapy alone.

SNL Image

The Swiss drugmaker's Tecentriq is part of a class of tumor-targeting drugs called checkpoint inhibitors. The therapy blocks the PD-L1 protein on cancer cells from linking with a partner arm on healthy cells — an interaction that prevents the spread of the disease.

The FDA has approved Tecentriq in combination with Avastin and chemotherapy for patients with non-squamous non-small cell lung cancer that has spread to other parts of the body, and does not have an abnormal EGFR or ALK gene. The immunotherapy also received U.S. approval for treating metastatic NSCLC whose disease progressed during or following platinum-containing chemotherapy.

The drug, also known as atezolizumab, is also used for treating certain types of breast cancer and bladder cancer.